Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
ADMA Biologics
About
ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases.
- Ramsey,New Jersey,United States
- 51 - 100
- https://www.admabiologics.com/
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $5M
- Industries
- Biotechnology,Health Care,Manufacturing,Medical
- Founded date
- Jan 1, 2004
- Number Of Employee
- 51 - 100
- Operating Status
- Active
- Stock Symbol
- nasdaq:ADMA
- Legal Name
- ADMA PLASMA BIOLOGICS INC.
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons.ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 7, 2022 | Post-IPO Equity | $60M | — | — | — | Detail |
| Mar 24, 2022 | Post-IPO Debt | $150M | 1 |
Hayfin Capital Management
|
— | Detail |
| Feb 6, 2020 | Post-IPO Equity | $82.30M | — | — | — | Detail |
| May 22, 2019 | Post-IPO Equity | $51.75M | — | — | — | Detail |
| Feb 12, 2019 | Post-IPO Debt | $72.50M | 1 |
Perceptive Advisors
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hayfin Capital Management
|
Yes | Post-IPO Debt |
|
Perceptive Advisors
|
Yes | Post-IPO Debt |
Marathon Asset Management
|
Yes | Post-IPO Debt |
|
|
Yes | Post-IPO Debt |
Burrill & Company
|
Yes | Series Unknown |
Hercules Capital
|
— | Post-IPO Debt |
Aisling Capital
|
— | Series Unknown |
Biomark Capital
|
— | Series Unknown |
Employee Profiles
Acquisition
ADMA Biologics has acquired 1 organizations. Their most recent acquisition was Biotest - Therapy business on Jun 6, 2017. They acquired Biotest - Therapy business for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Jun 6, 2017
|
Biotechnology | acquisition | — | Detail |
